Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Omega 3 pentaenoic acid · 1 trial · 1 indication
Percent change in triglycerides from baseline to end of treatment in the pharmacodynamic population
| Arm | Type | Description |
|---|---|---|
| Omega-3 pentaenoic acid (MAT9001) | EXPERIMENTAL | 2g MAT9001 capsules twice daily with meals |
| Icosapent ethyl (Vascepa) | ACTIVE_COMPARATOR | 2g Vascepa capsules twice daily with meals |
| Name | Type | Description |
|---|---|---|
| Omega 3 pentaenoic acid | DRUG | Encapsulated omega-3 pentaenoic acid |
| icosapent ethyl | DRUG | Encapsulated omega-3 acid ethyl esters |
Inclusion Criteria: * Male or female, ≥18 y of age * Judged to be in generally good health * Fasting triglycerides ≥150 mg/dL to ≤499 mg/dL during screening * Body mass index of ≥20.0 kg/m2 * No clinically significant findings in a 12-lead ECG or physical examination * Willing and able to undergo t...